Date posted: 24 January 2024
BRISTOL, UK, 24th January 2024. Scarlet Therapeutics were proud to see our scientific co-founder Ash Toye recognised by Sanius Health as one of the Top 80 Most Influential People and Advocates in Sickle Cell Disease, in part for his work in the RESTORE trial. This ongoing study investigates how long a mini blood transfusion of laboratory grown red blood cells survives in the human body compared with the same amount of standard red blood cells, the fundamentals of which underpins the work we do here at Scarlet.
Ash Toye, CSO of Scarlet Therapeutics, says: “It was a lovely and humbling surprise to learn that I had been included in such a prestigious list of advocates, clinicians, researchers and thought leaders. Thank you to my colleagues on the RESTORE trail and to Sanius Health for this recognition.”
Scarlet sends our congratulations to Prof. Ash Toye and the rest of the RESTORE team. Further information on Sanius can be found here and on the RESTORE trail here.
For press enquires please contact:
Alistair Irvine
Tel: +44 75077 86615
Email: press@scarlet-tx.com
Website: www.scarlet-tx.com
LinkedIn: Scarlet Therapeutics Ltd | LinkedIn
About Scarlet Therapeutics
Scarlet Therapeutics is developing a unique platform that generates novel red blood cell-based therapeutics to potentially treat a wide range of diseases. Initially targeted at the rare metabolic diseases, hyperammonemia and hyperoxaluria, this approach could also be used more broadly to target other metabolic diseases, cancer and autoimmune diseases. These therapeutic red blood cells (tRBCs) are very similar to standard red blood cells, which have many advantageous qualities including pervasive reach throughout the body, a long life and the ability to carry the active proteins within the RBC which are shielded from the immune system. Born out of more than a decade of research at the University of Bristol and the learning from the RESTORE clinical study, Scarlet also has an exclusive commercial licence for the widely used BEL-A cell line, which provides an alternative platform technology for production of red blood cells.